Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas

Author(s): David Hsieh.

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 23 , 2011

Become EABM
Become Reviewer

Abstract:

The discovery of discrete functional components in cancer systems advocates a paradigm shift in therapeutic design towards the targeted destruction of critical cellular constituents that fuel tumorigenic potential. In astrocytomas, malignant growth can be propagated and sustained by glioma stem cells (GSCs) endowed with highly efficient clonogenic and tumor initiation capacities. Given their disproportionate oncogenic contribution, GSCs are often considered the optimal targets for curative treatment because their eradication may subvert the refractory nature of GBMs. However, the close affinity of GSCs and normal neural stem cells (NSCs) is a cautionary note for off-target effects of GSC-based therapies. In fact, many parallels can be drawn between GSC and NSC functions, which ostensibly rely on a communal collection of stem cell-promoting transcription factors (TFs). Only through rigorous scrutiny of nuances in the stemness program of GSCs and NSCs may we clarify the pathogenic mechanisms of stemness factors and reveal processes exploited by cancer cells to co-opt stem cell traits. Importantly, discerning the specific requirements for GSC and NSC maintenance may be an essential requisite when assessing molecular targets for discriminatory targeting of GSCs with minimal sequelae.

Keywords: Glioblastoma, Cancer therapy, Cancer stem cells, Neural stem cells, tumors, neurogenesis, bevacizumab, oncogenes, gliomas, hypoxia

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 23
Year: 2011
Page: [2370 - 2385]
Pages: 16
DOI: 10.2174/138161211797249198
Price: $58

Article Metrics

PDF: 4